P&T Atopic Dermatitis

Syndicated P&T Session: Atopic Dermatitis

Three JAK inhibitors: Olumiant™ (baricitinib), Rinvoq™ (upadacitinib) and abrocitinib and one Interleukin Antibody (IL-13): tralokinumab have become available in the Atopic Dermatitis category. Will these new drugs cause a disruption of formulary classification and treatment choices? Are they ready to pose a threat to Dupixent™ (dupilumab): the first biologic therapy approved patients aged 6 years & older with moderate-to-severe AD?

Learn how you can use P&T Perspectives to:

  • Understand if these new drugs are ready to disrupt treatment choices for moderate to severe Atopic Dermatitis?
  • Observe if their clinical and/or economic value can pose a threat to Dupixent™
  • Identify any other differentiators or unexpected barriers that may impact your brand
  • And more

Interested in obtaining the full video and learning more about how you can take advantage of P&T Perspectives?



Witness the Actual Discussions: